Novo Sues Rival Lilly Over Weight-Loss Ads (Correct)
Share
Novo Nordisk A/S is suing rival drugmaker Eli Lilly & Co. for showing what it calls misleading ads about obesity drugs in the US. Novo says Lilly is using outdated information when comparing Novo's Wegovy to Lilly's Zepbound. John Kuckelman, Novo Nordisk Group general counsel and senior vice president, speaks on "Bloomberg Open Interest." Lilly says in a statement to Bloomberg that it's ads are "truthful" and "transparent" and the company will defend "vigorously" against the Novo lawsuit. (Corrects spelling of Novo Nordisk)